NO329663B1 - Anvendelse av en ¿-adrenergisk agonist og en farmasoytisk akseptabel bioadhesiv baerer i produksjon av et medikament - Google Patents

Anvendelse av en ¿-adrenergisk agonist og en farmasoytisk akseptabel bioadhesiv baerer i produksjon av et medikament Download PDF

Info

Publication number: NO329663B1
Authority: NO; Norway
Prior art keywords: adrenergic agonist; drug; use according; terbutaline; endometriosis
Prior art date: 1999-10-05

Application number

NO20021591A

Other languages

English (en)

Norwegian (no)

Other versions

NO20021591L (no

NO20021591D0 (no

Inventor

Howard L Levine

William J Bologna

Dominique De Ziegler

Original Assignee

Columbia Lab Bermuda Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-05

Filing date

2002-04-04

Publication date

2010-11-29

2002-04-04 Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd

2002-04-04 Publication of NO20021591D0 publication Critical patent/NO20021591D0/no

2002-05-28 Publication of NO20021591L publication Critical patent/NO20021591L/no

2010-11-29 Publication of NO329663B1 publication Critical patent/NO329663B1/no

Links

239000000227 bioadhesive Substances 0.000 title claims description 21
239000003814 drug Substances 0.000 title claims description 16
229940079593 drug Drugs 0.000 title claims description 12
238000004519 manufacturing process Methods 0.000 title claims description 11
239000000048 adrenergic agonist Substances 0.000 title 1
239000000808 adrenergic beta-agonist Substances 0.000 claims abstract description 40
201000009273 Endometriosis Diseases 0.000 claims abstract description 31
238000011282 treatment Methods 0.000 claims abstract description 18
230000035558 fertility Effects 0.000 claims abstract description 10
208000000509 infertility Diseases 0.000 claims abstract description 10
230000036512 infertility Effects 0.000 claims abstract description 10
231100000535 infertility Toxicity 0.000 claims abstract description 10
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical group CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 29
229960000195 terbutaline Drugs 0.000 claims description 28
229920000642 polymer Polymers 0.000 claims description 24
210000004877 mucosa Anatomy 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 4
230000036765 blood level Effects 0.000 claims description 2
230000000694 effects Effects 0.000 abstract description 19
239000000203 mixture Substances 0.000 abstract description 18
238000002360 preparation method Methods 0.000 abstract description 12
238000000034 method Methods 0.000 abstract description 6
230000009885 systemic effect Effects 0.000 abstract description 3
206010013935 Dysmenorrhoea Diseases 0.000 description 9
230000008602 contraction Effects 0.000 description 9
210000004291 uterus Anatomy 0.000 description 9
229920000148 Polycarbophil calcium Polymers 0.000 description 8
229950005134 polycarbophil Drugs 0.000 description 8
230000032258 transport Effects 0.000 description 8
229920002125 Sokalan® Polymers 0.000 description 7
208000036029 Uterine contractions during pregnancy Diseases 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
210000003101 oviduct Anatomy 0.000 description 7
239000003826 tablet Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000008187 granular material Substances 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
239000008101 lactose Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
230000011599 ovarian follicle development Effects 0.000 description 6
230000027758 ovulation cycle Effects 0.000 description 6
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
229960001631 carbomer Drugs 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
208000005171 Dysmenorrhea Diseases 0.000 description 4
101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 4
102100023123 Mucin-16 Human genes 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
229940099112 cornstarch Drugs 0.000 description 4
239000003431 cross linking reagent Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
230000004720 fertilization Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
210000004914 menses Anatomy 0.000 description 4
230000002175 menstrual effect Effects 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
208000012661 Dyskinesia Diseases 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000035587 bioadhesion Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000003906 humectant Substances 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000002632 myometrial effect Effects 0.000 description 3
230000016087 ovulation Effects 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
206010000084 Abdominal pain lower Diseases 0.000 description 2
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000000450 Pelvic Pain Diseases 0.000 description 2
208000006399 Premature Obstetric Labor Diseases 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000006071 cream Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000000142 dyskinetic effect Effects 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
230000003325 follicular Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000001660 hyperkinetic effect Effects 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
230000029849 luteinization Effects 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000007441 retrograde transport Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
235000010199 sorbic acid Nutrition 0.000 description 2
239000004334 sorbic acid Substances 0.000 description 2
229940075582 sorbic acid Drugs 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000008346 uterine blood flow Effects 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
DSAYAFZWRDYBQY-UHFFFAOYSA-N 2,5-dimethylhexa-1,5-diene Chemical compound CC(=C)CCC(C)=C DSAYAFZWRDYBQY-UHFFFAOYSA-N 0.000 description 1
BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010043137 Actomyosin Proteins 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010052895 Coronary artery insufficiency Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010023379 Ketoacidosis Diseases 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000037093 Menstruation Disturbances Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
208000005107 Premature Birth Diseases 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
206010065951 Retrograde menstruation Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
206010046823 Uterine spasm Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960004620 bitolterol Drugs 0.000 description 1
FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940085237 carbomer-980 Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000004035 construction material Substances 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
229940000593 crinone Drugs 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
231100000502 fertility decrease Toxicity 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
229960000708 hexoprenaline Drugs 0.000 description 1
OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
229960004819 isoxsuprine Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
239000002075 main ingredient Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229940087419 nonoxynol-9 Drugs 0.000 description 1
229920004918 nonoxynol-9 Polymers 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000001139 pH measurement Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008213 purified water Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229960001634 ritodrine Drugs 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
150000003839 salts Chemical group 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
SDVOJIRXJLEGCY-ZFRLFKIJSA-N spc3 Chemical compound N([C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCCCC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCCNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCCNC(=O)[C@H](CCCCNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)NCCC(O)=O)C(=O)CNC(=O)[C@@H]1CCCN1C(=O)CN SDVOJIRXJLEGCY-ZFRLFKIJSA-N 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
208000010422 uterine anomalies Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
230000002087 whitening effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NO20021591A 1999-10-05 2002-04-04 Anvendelse av en ¿-adrenergisk agonist og en farmasoytisk akseptabel bioadhesiv baerer i produksjon av et medikament NO329663B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15775499P	1999-10-05	1999-10-05
US66838400A	2000-09-25	2000-09-25
PCT/EP2000/009708 WO2001024788A2 (en)	1999-10-05	2000-10-04	Treating endometriosis or infertility, or improving fertility

Publications (3)

Publication Number	Publication Date
NO20021591D0 NO20021591D0 (no)	2002-04-04
NO20021591L NO20021591L (no)	2002-05-28
NO329663B1 true NO329663B1 (no)	2010-11-29

Family

ID=26854456

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021591A NO329663B1 (no)	1999-10-05	2002-04-04	Anvendelse av en ¿-adrenergisk agonist og en farmasoytisk akseptabel bioadhesiv baerer i produksjon av et medikament

Country Status (28)

Country	Link
EP (1)	EP1220667B1 (de)
JP (2)	JP2003510354A (de)
KR (1)	KR100738724B1 (de)
CN (1)	CN1218694C (de)
AR (1)	AR028487A1 (de)
AT (1)	ATE271860T1 (de)
AU (1)	AU780736B2 (de)
BR (1)	BR0014548A (de)
CA (1)	CA2385974C (de)
CO (1)	CO5251423A1 (de)
DE (1)	DE60012554T2 (de)
DK (1)	DK1220667T3 (de)
ES (1)	ES2223581T3 (de)
GE (1)	GEP20043313B (de)
HK (1)	HK1044120B (de)
HU (1)	HU225990B1 (de)
IL (2)	IL148784A0 (de)
MA (1)	MA25501A1 (de)
MX (1)	MXPA02003453A (de)
MY (1)	MY129518A (de)
NO (1)	NO329663B1 (de)
NZ (1)	NZ518429A (de)
PE (1)	PE20010742A1 (de)
PT (1)	PT1220667E (de)
TR (1)	TR200200899T2 (de)
TW (1)	TWI280877B (de)
UA (1)	UA74168C2 (de)
WO (1)	WO2001024788A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101327326A (zh) *	2001-10-29	2008-12-24	哥伦比亚实验室(百慕大群岛)有限公司	阴道给药治疗骨盆痛和不孕症的抗节律障碍剂
US8425892B2 (en)	2001-10-29	2013-04-23	Columbia Laboratories, Inc.	Extended, controlled-release pharmaceutical compositions using charged polymers
ES2237298B1 (es)	2003-07-16	2006-11-01	Italfarmaco, S.A.	Formulaciones mucoadhesivas semisolidas.
EP1872775A1 (de)	2006-06-29	2008-01-02	Polichem S.A.	Verwendung einer hydrophilen Matrix, die ein Polyacrylsäurederivat, einen Celluloseether und ein Zerfallsmittel enthält, für die Herstellung eines Medikamentes zur Behandlung weiblicher Genitalstörungen
ES2344673B1 (es)	2008-08-07	2011-05-03	Italfarmaco, S.A.	Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es)	2008-12-19	2011-04-28	Italfarmaco, S.A.	Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
MX2012010327A (es) *	2010-03-22	2012-11-16	Repros Therapeutics Inc	Composiciones y metodos para la administracion no toxica de antiprogestinas.
KR101010031B1 (ko) *	2010-12-08	2011-01-21	류상범	흡수식 냉온수기용 엘리미네이터
SG11201407397WA (en)	2012-05-31	2014-12-30	Repros Therapeutics Inc	Formulations and methods for vaginal delivery of antiprogestins
AU2013338305B2 (en)	2012-11-02	2018-06-07	Allergan pharmaceuticals International Ltd.	Methods and compositions for treating progesterone-dependent conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4241087A (en) *	1979-04-02	1980-12-23	William H. Rorer, Inc.	Dysmenorrhea treatment
AU5068090A (en) *	1989-03-07	1990-09-13	Adeza Biomedical Corporation	Endometriosis diagnosis methods and reagents
JP2602456B2 (ja) *	1990-04-12	1997-04-23	雪印乳業株式会社	子宮内膜症治療剤
IT1251114B (it) *	1991-07-26	1995-05-04	Farcon Ag	Forme farmaceutiche antivirali per applicazione vaginale
DE69819748T2 (de) *	1997-09-12	2004-09-30	Columbia Laboratories (Bermuda) Ltd.	Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen

2000
- 2000-04-10 UA UA2002043631A patent/UA74168C2/uk unknown
- 2000-10-03 MY MYPI20004608A patent/MY129518A/en unknown
- 2000-10-03 PE PE2000001044A patent/PE20010742A1/es not_active Application Discontinuation
- 2000-10-04 HU HU0203050A patent/HU225990B1/hu unknown
- 2000-10-04 EP EP00964272A patent/EP1220667B1/de not_active Expired - Lifetime
- 2000-10-04 CA CA2385974A patent/CA2385974C/en not_active Expired - Fee Related
- 2000-10-04 IL IL14878400A patent/IL148784A0/xx active IP Right Grant
- 2000-10-04 NZ NZ518429A patent/NZ518429A/en not_active IP Right Cessation
- 2000-10-04 PT PT00964272T patent/PT1220667E/pt unknown
- 2000-10-04 WO PCT/EP2000/009708 patent/WO2001024788A2/en active IP Right Grant
- 2000-10-04 CO CO00075387A patent/CO5251423A1/es not_active Application Discontinuation
- 2000-10-04 JP JP2001527787A patent/JP2003510354A/ja active Pending
- 2000-10-04 DE DE60012554T patent/DE60012554T2/de not_active Expired - Lifetime
- 2000-10-04 TR TR2002/00899T patent/TR200200899T2/xx unknown
- 2000-10-04 BR BR0014548-3A patent/BR0014548A/pt not_active Application Discontinuation
- 2000-10-04 ES ES00964272T patent/ES2223581T3/es not_active Expired - Lifetime
- 2000-10-04 AT AT00964272T patent/ATE271860T1/de active
- 2000-10-04 AU AU75250/00A patent/AU780736B2/en not_active Ceased
- 2000-10-04 CN CNB008138079A patent/CN1218694C/zh not_active Expired - Fee Related
- 2000-10-04 GE GE4769A patent/GEP20043313B/en unknown
- 2000-10-04 AR ARP000105228A patent/AR028487A1/es unknown
- 2000-10-04 DK DK00964272T patent/DK1220667T3/da active
- 2000-10-04 KR KR1020027004330A patent/KR100738724B1/ko not_active IP Right Cessation
- 2000-10-04 MX MXPA02003453A patent/MXPA02003453A/es active IP Right Grant
- 2000-10-27 TW TW089120706A patent/TWI280877B/zh not_active IP Right Cessation
2002
- 2002-03-20 IL IL148784A patent/IL148784A/en not_active IP Right Cessation
- 2002-04-04 MA MA26584A patent/MA25501A1/fr unknown
- 2002-04-04 NO NO20021591A patent/NO329663B1/no not_active IP Right Cessation
- 2002-08-01 HK HK02105660.6A patent/HK1044120B/zh not_active IP Right Cessation
2009
- 2009-10-29 JP JP2009249023A patent/JP2010018639A/ja active Pending

Also Published As

Publication number	Publication date
PT1220667E (pt)	2004-11-30
HU225990B1 (en)	2008-02-28
DE60012554T2 (de)	2005-11-24
IL148784A (en)	2006-12-31
MA25501A1 (fr)	2002-07-01
HK1044120A1 (en)	2002-10-11
HUP0203050A2 (hu)	2003-02-28
ES2223581T3 (es)	2005-03-01
NO20021591L (no)	2002-05-28
CN1218694C (zh)	2005-09-14
AR028487A1 (es)	2003-05-14
WO2001024788A3 (en)	2001-12-06
EP1220667B1 (de)	2004-07-28
PE20010742A1 (es)	2001-07-19
CA2385974C (en)	2010-01-26
ATE271860T1 (de)	2004-08-15
GEP20043313B (en)	2004-03-10
MY129518A (en)	2007-04-30
AU780736B2 (en)	2005-04-14
UA74168C2 (uk)	2005-11-15
CA2385974A1 (en)	2001-04-12
WO2001024788A2 (en)	2001-04-12
BR0014548A (pt)	2002-06-04
DE60012554D1 (de)	2004-09-02
CN1377264A (zh)	2002-10-30
TR200200899T2 (tr)	2002-07-22
KR20020062285A (ko)	2002-07-25
HUP0203050A3 (en)	2006-02-28
DK1220667T3 (da)	2004-12-06
JP2003510354A (ja)	2003-03-18
MXPA02003453A (es)	2002-08-20
AU7525000A (en)	2001-05-10
IL148784A0 (en)	2002-09-12
TWI280877B (en)	2007-05-11
JP2010018639A (ja)	2010-01-28
CO5251423A1 (es)	2003-02-28
EP1220667A2 (de)	2002-07-10
NZ518429A (en)	2004-02-27
NO20021591D0 (no)	2002-04-04
HK1044120B (zh)	2004-12-17
KR100738724B1 (ko)	2007-07-12

Publication	Publication Date	Title
CA2303339C (en)	2006-12-12	A pharmaceutical composition for treating dysmenorrhea and premature labor
US20110053845A1 (en)	2011-03-03	Localized vaginal delivery without detrimental blood levels
JP2010018639A (ja)	2010-01-28	子宮内膜炎または不妊症の処置および妊孕性の改善
CN101917848B (zh)	2014-02-12	用于治疗子宫收缩过强病症的s-烷基异硫脲衍生物
US6818672B1 (en)	2004-11-16	Treating endometriosis or infertility, or improving fertility
US12011423B2 (en)	2024-06-18	S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
EP1356806A1 (de)	2003-10-29	Arzneimittel zur Behandlung von Dysmenorrhöe und verfrühten Wehen
UA62983C2 (en)	2004-01-15	Pharmaceutical composition for treating or preventing dysmenorrhea or premature labor
MXPA00002448A (en)	2001-03-05	A pharmaceutical composition for treating dysmenorrhea and premature labor

Legal Events

Date	Code	Title	Description
2015-05-26	MM1K	Lapsed by not paying the annual fees